{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T03:03:42Z","timestamp":1769483022917,"version":"3.49.0"},"reference-count":42,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Curium"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMAHP"],"abstract":"<jats:p>Introduction: [18F]-DCFPyL (Piflufolastat [18F]) is a prostate-specific membrane antigen (PSMA)-targeted position emission tomography (PET) radiotracer for detecting the biochemical recurrence (BCR) of prostate cancer (PCa). This study evaluates its economic impact compared with [68Ga]-PSMA-11, [18F]-FCH, and [18F]-PSMA-1007 from the Spanish National Healthcare System\u2019s perspective. Methods: A cost\u2013consequence model, over a 5-year time horizon, simulated the diagnostic and treatment pathway based on radiotracer-specific accuracy and disease localization. Treatment options included a radical prostatectomy, radiation therapy, androgen deprivation therapy (ADT), and radiation therapy + ADT. Costs were calculated for true\/false positives and negatives. Due to limited data availability, key inputs were informed by expert opinions, supported by published meta-analyses, public sources, and literature. Officially published Spanish prices were applied: EUR 2000 for [18F]-DCFPyL, [68Ga]-PSMA-11, and [18F]-PSMA-1007, and EUR 1144 for [18F]-FCH. Results: The use of [18F]-DCFPyL led to fewer unnecessary therapies; specifically, it led to 11,229 (74%) fewer than [68Ga]-PSMA-11, and 5180 (56%) and 7771 (66%) fewer than [18F]-FCH and [18F]-PSMA-1007, respectively. It achieved significant cost savings for repeated testing: EUR 15M (43%) versus [68Ga]-PSMA-11, EUR 37M (65%) versus [18F]-FCH, and EUR 27M (58%) versus [18F]-PSMA-1007. Cost savings for false positives were EUR 15M (50%) against [68Ga]-PSMA-11, EUR 22M (60%) versus [18F]-FCH, and EUR 29M (66%) compared with [18F]-PSMA-1007. The cost per correct diagnosis was reduced by EUR 198 (8%) compared with [68Ga]-PSMA-11 and EUR 377 (15%) relative to [18F]-PSMA-1007, while showing a EUR 635 (40%) increase compared with [18F]-FCH. Conclusions: [18F]-DCFPyL offers a cost-saving option for BCR detection within the Spanish National Healthcare System by reducing the number of unnecessary therapies, the cost of false positives, and repeat testing compared with alternative radiotracers. These improvements support the potential for better diagnostic outcomes and more informed downstream clinical decision-making.<\/jats:p>","DOI":"10.3390\/jmahp14010007","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:13:48Z","timestamp":1769444028000},"page":"7","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating [18F]-DCFPyL for Detecting Prostate Cancer Recurrence: A Cost\u2013Consequence Comparison with Alternative PET Radiotracers in Spain"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4220-8507","authenticated-orcid":false,"given":"Tiago","family":"Matos","sequence":"first","affiliation":[{"name":"Alira Health, Global Health Economics, 4057 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrunmayee","family":"Godbole","sequence":"additional","affiliation":[{"name":"Alira Health, Global Health Economics, 08029 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6647-2961","authenticated-orcid":false,"given":"Rithvik","family":"Badinedi","sequence":"additional","affiliation":[{"name":"Alira Health, Global Health Economics, London WC1V 6DF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-4097","authenticated-orcid":false,"given":"Madhusubramanian","family":"Muthukumar","sequence":"additional","affiliation":[{"name":"Alira Health, Global Health Economics, London WC1V 6DF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Hodolic","sequence":"additional","affiliation":[{"name":"Curium, 75008 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Tchouen","sequence":"additional","affiliation":[{"name":"Curium, 75008 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Berthon","sequence":"additional","affiliation":[{"name":"Curium, 75008 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"ref_1","first-page":"e48252","article-title":"An In-Depth Look Into the Epidemiological and Etiological Aspects of Prostate Cancer: A Literature Review","volume":"15","author":"Salameh","year":"2023","journal-title":"Cureus"},{"key":"ref_2","unstructured":"SEOM (2025, September 01). The Cancer Figures in Spain. Available online: https:\/\/seom.org\/dmcancer\/cifras-del-cancer\/."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Darb\u00e0, J., and Ascanio, M. (2024). Prostate cancer in Spain: A retrospective database analysis of hospital incidence and the direct medical costs. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0298764"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/cncr.10977","article-title":"Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above","volume":"95","author":"Kupelian","year":"2002","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10585-020-10027-1","article-title":"Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET\/MRI-based imaging in patients with biochemical recurrence of prostate cancer","volume":"37","author":"Gordon","year":"2020","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2013.04.019","article-title":"The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET\/CT in prostate cancer: A systematic review and meta-analysis","volume":"64","author":"Umbehr","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_7","first-page":"272","article-title":"The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research","volume":"32","author":"Ristau","year":"2014","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","article-title":"Is Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial","volume":"79","author":"Hofman","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2017.07.011","article-title":"Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease","volume":"8","author":"Evans","year":"2018","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s00261-020-02427-4","article-title":"Positron emission tomography (PET) radiotracers for prostate cancer imaging","volume":"45","author":"Walker","year":"2020","journal-title":"Abdom. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bju.14828","article-title":"Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer","volume":"124","author":"Yaxley","year":"2019","journal-title":"BJU Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.7150\/thno.44584","article-title":"Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11 PET","volume":"10","author":"Ferraro","year":"2020","journal-title":"Theranostics"},{"key":"ref_13","first-page":"96","article-title":"Imaging of prostate cancer with PET\/CT using [18F]-Fluorocholine","volume":"5","author":"Vali","year":"2015","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1007\/s00259-021-05620-9","article-title":"Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: A Markov chain decision analysis","volume":"49","author":"Alberts","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","article-title":"Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: A systematic review and network meta-analysis","volume":"48","author":"Alberts","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"ref_16","unstructured":"FDA (2025, September 01). FDA Approves Second PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer, Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer."},{"key":"ref_17","unstructured":"EMA (2025, September 01). Pylclari: EPAR\u2014Medicine Overview, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pylclari."},{"key":"ref_18","unstructured":"(2025, September 01). NCT02981368. Study of 18F-DCFPyL PET\/CT Imaging in Patients with Prostate Cancer (OSPREY), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02981368."},{"key":"ref_19","unstructured":"(2025, September 01). NCT03739684. Study of 18F-DCFPyL PET\/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03739684."},{"key":"ref_20","unstructured":"EU Clinical Trials Register (2025, September 01). Clinical Trials. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000121-37\/results."},{"key":"ref_21","unstructured":"Pylclari SmPC (2025, September 01). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pylclari-epar-product-information_en.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1749362","DOI":"10.1080\/20016689.2020.1749362","article-title":"Cost-consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer","volume":"8","author":"Jensen","year":"2020","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"le Guevelou, J., Achard, V., Mainta, I., Zaidi, H., Garibotto, V., Latorzeff, I., Sargos, P., M\u00e9nard, C., and Zilli, T. (2021). PET\/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.742093"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102171","DOI":"10.1016\/j.clgc.2024.102171","article-title":"Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale","volume":"22","author":"Sternberg","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pan, K.H., Wang, J.F., Wang, C.Y., Nikzad, A.A., Kong, F.Q., Jian, L., Zhang, Y.Q., Lu, X.M., Xu, B., and Wang, Y.L. (2021). Evaluation of 18F-DCFPyL PSMA PET\/CT for Prostate Cancer: A Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.597422"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.2967\/jnumed.118.219501","article-title":"Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology","volume":"60","author":"Hope","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bju.12953","article-title":"Clinical utility of 18F-fluorocholine positron-emission tomography\/computed tomography (PET\/CT) in biochemical relapse of prostate cancer after radical treatment: Results of a multicentre study","volume":"115","year":"2015","journal-title":"BJU Int."},{"key":"ref_31","first-page":"88","article-title":"Diagnostic accuracy of 18F-PSMA-1007 PET\/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis","volume":"25","author":"Liu","year":"2022","journal-title":"Hell J. Nucl. Med."},{"key":"ref_32","unstructured":"Ministerio De Sanida (2025, September 01). CIPM Agreements and Information Notes, Available online: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/acuerdosNotasInformativas\/home.htm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.juro.2018.07.034","article-title":"Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment","volume":"200","author":"Govers","year":"2018","journal-title":"J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12094-018-1921-5","article-title":"Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: A real-world data analysis","volume":"21","author":"Koninckx","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_35","first-page":"1","article-title":"Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain","volume":"6","author":"Velasco","year":"2018","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1080\/13696998.2019.1661581","article-title":"Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance","volume":"22","author":"Barqawi","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.1111\/j.1464-410X.2012.10928.x","article-title":"Prospective assessment of histological serial sectioning of pelvic lymph nodes in prostate cancer: A cost-benefit analysis","volume":"110","author":"Schilling","year":"2012","journal-title":"BJU Int."},{"key":"ref_38","unstructured":"(2025, September 01). Osakidetza. Available online: https:\/\/www.osakidetza.euskadi.eus\/portada."},{"key":"ref_39","unstructured":"Ministerio De Sanida (2025, September 01). Acuerdos De La Comision Interministerial De Precios De Los Medicamentos, Available online: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/acuerdosNotasInformativas\/docs\/ACUERDOS_CIPM_246.pdf."},{"key":"ref_40","unstructured":"Ministerio De Sanida (2025, September 01). Acuerdos De La Comision Interministerial De Precios De Los Medicamentos, Available online: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/acuerdosNotasInformativas\/docs\/ACUERDOS_CIPM_238.pdf."},{"key":"ref_41","unstructured":"Ministerio De Sanida (2025, September 01). Nota Informativa de la Reunion de la Comision Interministerial de Precios de los Medicamentos, Available online: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/acuerdosNotasInformativas\/docs\/ACUERDOS_DE_LA_CIPM_177_web.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.gaceta.2010.10.008","article-title":"Cost comparison of three treatments for localized prostate cancer in Spain: Radical prostatectomy, prostate brachytherapy and external 3D conformal radiotherapy","volume":"25","author":"Cots","year":"2011","journal-title":"Gac. Sanit."}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/1\/7\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:45:15Z","timestamp":1769445915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/1\/7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jmahp14010007"],"URL":"https:\/\/doi.org\/10.3390\/jmahp14010007","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}